Ulrich Pfeffer
Overview
Explore the profile of Ulrich Pfeffer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
3151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reggiani F, El Rashed Z, Petito M, Pfeffer M, Morabito A, Tanda E, et al.
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38339073
Uveal melanoma (UM) is the most common primary intraocular malignancy with a limited five-year survival for metastatic patients. Limited therapeutic treatments are currently available for metastatic disease, even if the...
2.
Reggiani F, Ambrosio M, Croce M, Tanda E, Spagnolo F, Raposio E, et al.
Int J Mol Sci
. 2023 Nov;
24(21).
PMID: 37958591
The metastatic risk of uveal melanoma (UM) is defined by a limited number of molecular lesions, somatic mutations (SF3B1 and BAP1), and copy number alterations (CNA): monosomy of chromosome 3...
3.
Amaro A, Pfeffer U
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835454
Before a tumor is diagnosed and surgically removed, it has been growing for many months or even years [...].
4.
Minuzzo S, Agnusdei V, Pinazza M, Amaro A, Sacchetto V, Pfeffer U, et al.
Exp Hematol Oncol
. 2023 Sep;
12(1):76.
PMID: 37667380
T-cell acute lymphoblastic leukemia (T-ALL) is a hematologic tumor, characterized by several genetic alterations, that constitutes 15% of pediatric and 25% of adult ALL. While with current therapeutic protocols children...
5.
Amaro A, Reggiani F, Fenoglio D, Gangemi R, Tosi A, Parodi A, et al.
J Exp Clin Cancer Res
. 2023 Mar;
42(1):67.
PMID: 36934257
Background: The combination of Programmed Cell Death 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) blockade has dramatically improved the overall survival rate for malignant melanoma. Immune checkpoint blockers (ICBs)...
6.
Amaro A, Gangemi R, Emionite L, Castagnola P, Filaci G, Jager M, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765842
Background: Metastatic uveal melanoma (MUM) is a highly aggressive, therapy-resistant disease. Driver mutations in Gα-proteins GNAQ and GNA11 activate MAP-kinase and YAP/TAZ pathways of oncogenic signalling. MAP-kinase and MEK-inhibitors do...
7.
Amaro A, Pfeffer M, Pfeffer U, Reggiani F
Biomedicines
. 2022 Dec;
10(12).
PMID: 36551996
There is a growing number of multi-domain genomic datasets for human tumors. Multi-domain data are usually interpreted after separately analyzing single-domain data and integrating the results post hoc. Data fusion...
8.
Grottoli M, Carrega P, Zullo L, Dellepiane C, Rossi G, Parisi F, et al.
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291830
Immune checkpoint inhibitors (ICIs) immunotherapy has represented a breakthrough in cancer treatment. Clinical use of ICIs has shown an acceptable safety profile and promising antitumor activity. Nevertheless, some patients do...
9.
Bertoni A, Penco F, Mollica H, Bocca P, Prigione I, Corcione A, et al.
J Allergy Clin Immunol
. 2022 Jul;
150(4):796-805.
PMID: 35835255
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may result in a severe pneumonia associated with elevation of blood inflammatory parameters, reminiscent of cytokine storm syndrome. Steroidal anti-inflammatory therapies...
10.
Piaggio F, Croce M, Reggiani F, Monti P, Bernardi C, Ambrosio M, et al.
Eur J Cancer
. 2022 May;
170:27-41.
PMID: 35580369
Background And Aim Of The Study: Mutations in the Gα-genes GNAQ and GNA11 are found in 85-90% of uveal melanomas (UM). Aim of the study is to understand whether the...